SEOM guidelines on thrombosis in cancer patients

Clinical and Translational Oncology

Volumn 13, Issue 8, 2011, Pages 592-596

  Muñoz, Andrés J ^a   Viñolas, Nuria ^b   Cubedo, Ricardo ^c   Isla, Dolores ^d  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Anticoagulation; Cancer; Guidelines; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTIVITAMIN K; DALTEPARIN; DEXAMETHASONE; ENOXAPARIN; FONDAPARINUX; HEPARIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; THALIDOMIDE; TINZAPARIN; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; COMPRESSION GARMENT; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; INCIDENTAL FINDING; LONG TERM CARE; LOW DRUG DOSE; LUNG EMBOLISM; MORBIDITY; MULTIPLE MYELOMA; PHASE 3 CLINICAL TRIAL (TOPIC); POSTTHROMBOSIS SYNDROME; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SURGICAL PATIENT; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM; CENTRAL VENOUS CATHETERIZATION; MEDICAL SOCIETY; METHODOLOGY; NEOPLASM; ONCOLOGY; THROMBOSIS; TIME; TREATMENT OUTCOME;

ANTICOAGULANTS; CATHETERIZATION, CENTRAL VENOUS; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; RECURRENCE; RISK FACTORS; SOCIETIES, MEDICAL; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84855401312     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0703-0     Document Type: Article

References (26)

1. Khorana AA, Francis CW, Culakova E et al (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5:632-634 (Pubitemid 46680709)
2. Bloom JW, Doggen CJ, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293: 715-722 (Pubitemid 40216041)
3. Sørensen HT, Mellemkjaer L, Olsen JH et al (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846-1850 (Pubitemid 32104130)
4. Khorana AA, Connolly GC (2009) Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 27:4839-4847
5. Cohen AT, Davidson BL, Gallus AS et al (2006) ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 332:325-329
6. Alikhan R, Cohen AT, Combe S et al (2003) Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 14:341-346 (Pubitemid 36688187)
7. Leizorovicz A, Cohen AT, Turpie AG et al (2004) PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110:874-879 (Pubitemid 39096017)
8. Alikhan R, Cohen AT (2009) Heparin for the prevention of venous thromboembolism in general medical patients (excluding stroke and myocardial infarction). Cochrane Database Syst Rev (3): CD003747
9. Mismetti P, Laporte-Simitsidis S, Tardy B et al (2000) Prevention of venous thromboembolism in internal medicine with unfractionated or lowmolecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 83:14-19 (Pubitemid 30045469)
10. Agnelli G, Bolis G, Capussotti L et al (2006) A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 243:89-95 (Pubitemid 43054059)
11. Bergqvist D, Agnelli G, Cohen AT et al (2002) Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346:975-980 (Pubitemid 34983247)
12. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P et al (2006) Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 4:2384-2390 (Pubitemid 44575433)
13. Khorana AA, Kuderer NM, Culakova E et al (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902-4907
14. Khorana AA, Streiff MB, Farge D et al (2009) Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 27:4919-4926
15. Palumbo A, Cavo M, Bringhen S et al (2011) Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 29:986-993
16. Akl EA, Kamath G, Yosuico V et al (2008) Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a metaanalysis. Cancer 112:2483-2492
17. Shivakumar SP, Anderson DR, Couban S (2009) Catheter-associated thrombosis in patients with malignancy. J Clin Oncol 27:4858-4864
18. Kearon C, Kahn SR, Agnelli G et al (2008) Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:454S-545S (Pubitemid 351892971)
19. Lee AY, Levine MN, Baker RI et al (2003) Lowmolecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349: 146-153 (Pubitemid 36818784)
20. Deitcher SR, Kessler CM, Merli G et al (2006) ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 12:389-396 (Pubitemid 44359237)
21. Meyer G, Marjanovic Z, Valcke J et al (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162: 1729-1735
22. Hull RD, Pineo GF, Brant RF et al (2006) Longterm low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. LITE Trial Investigators. Am J Med 119: 1062-1072 (Pubitemid 44826932)
23. Akl EA, Barba M, Rohilla S et al (2008) Lowmolecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a Cochrane systematic review. J Exp Clin Cancer Res 27:1-22
24. Falanga A, Rickles FR. Management of thrombohemorrhagic syndromes (THS) in hematologic malignancies. Hematology Am Soc Hematol Educ Program 165-171, doi:2007/1/165 [pii] 10.1182/asheducation-2007.1.165
25. Kahn SR (2006) The post-thrombotic syndrome: progress and pitfalls. Br J Haematol 134:357-365 (Pubitemid 44079549)
26. Kuderer NM, Ortel TL, Francis CW (2009) Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol 27:4902-4911